1. Home
  2. PRZO vs NCEL Comparison

PRZO vs NCEL Comparison

Compare PRZO & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$0.53

Market Cap

18.6M

Sector

N/A

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$3.56

Market Cap

17.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRZO
NCEL
Founded
2014
2008
Country
Israel
Switzerland
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
17.2M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
PRZO
NCEL
Price
$0.53
$3.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.8M
30.7K
Earning Date
03-26-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$1.83
52 Week High
$2.15
$5.12

Technical Indicators

Market Signals
Indicator
PRZO
NCEL
Relative Strength Index (RSI) 41.44 58.05
Support Level $0.45 $2.95
Resistance Level $0.82 $3.62
Average True Range (ATR) 0.06 0.26
MACD -0.01 0.03
Stochastic Oscillator 4.48 90.56

Price Performance

Historical Comparison
PRZO
NCEL

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: